Compare DexCom, Inc. (DXCM) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Fox Corp Class A — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Fox Corp Class A trades at $63.88 (market cap $25.36B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Fox Corp Class A pays a 0.91% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Fox Corp Class A for 34 Days on average.
| DXCM | FOXA | |
|---|---|---|
Market Cap | $31.86B | $25.36B |
Volume | 3,607,070 | 2,566,954 |
Sector | Health | Media |
52-Week High | $92.34 | $76.11 |
52-Week Low | $54.84 | $48.79 |
Typical Hold Time | 62 Days | 34 Days |
Enterprise Value | $31.32B | $28.72B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
FOXA trades at $62.70, up 1.0% today, with a bearish technical signal but strong fundamentals including a P/E of 16.55 and net income margin of 9.84%. Recent earnings beats and a consensus analyst price target of $72.00 suggest upside potential, though the pending Roku acquisition faces DOJ scrutiny, adding regulatory risk. Cash flow improved in 2025, but a projected net cash outflow in 2026 warrants monitoring.
The outlook is mixed: solid profitability and analyst support contrast with technical weakness and acquisition uncertainty. Investors may find value if the Roku deal proceeds smoothly, but regulatory delays or integration challenges pose significant downside risks to near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
